STOCK TITAN

IperionX tops FY2026 director fee cap by US$119K

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

IperionX Limited (IPX) disclosed a breach of ASX Listing Rule 10.17A after aggregate non-executive director cash fees exceeded the shareholder-approved US$300,000 annual pool by US$13,804 in FY2024, US$38,796 in FY2025 and US$119,007 in FY2026. The company attributed the failure to seek approval for a higher pool to administrative oversight.

FY2027 gross NED cash compensation was reduced to US$300,000, including superannuation, effective July 1, 2026. Affected directors agreed to repay historical excesses through offsets; net FY2027 NED cash fees are currently expected to total US$128,392. IperionX is seeking shareholder approval to raise the pool to US$700,000; if approved, net FY2027 fees would total US$288,392. The company also says it added quarterly checks against the fee cap.

Approved annual NED cash fee pool US$300,000 Shareholders approved the pool on November 25, 2021.
FY2024 excess fees US$13,804 Amount by which aggregate NED cash fees exceeded the approved pool.
FY2025 excess fees US$38,796 Amount by which aggregate NED cash fees exceeded the approved pool.
FY2026 excess fees US$119,007 Amount by which aggregate NED cash fees exceeded the approved pool.
FY2027 gross NED cash compensation US$300,000 Including superannuation; effective July 1, 2026.
Expected FY2027 net NED cash fees US$128,392 Currently expected after agreed repayment offsets.
Proposed aggregate NED fee pool US$700,000 Subject to shareholder approval.
Expected FY2027 net NED cash fees if approved US$288,392 After agreed deductions, if the fee-pool increase is approved.
ASX Listing Rule 10.17A regulatory
"identified a breach of ASX Listing Rule 10.17A"
aggregate annual cash fee pool financial
"approved an aggregate annual cash fee pool of US$300,000"
superannuation financial
"US$300,000, including superannuation"
Superannuation is a long-term retirement savings system where employers (and sometimes workers) regularly put money into an account or fund that grows until retirement, much like a workplace piggy bank managed by professionals. It matters to investors because these funds pool huge amounts of money and invest in stocks, bonds and property, so their choices and any changes in rules or tax treatment can shift market demand, company funding and asset prices.
repayment offsets financial
"repay the historical excess fees through offsets"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much did IperionX’s non-executive director fees exceed the approved pool by?

The excess was US$13,804 in FY2024, US$38,796 in FY2025 and US$119,007 in FY2026. The company said affected directors agreed to repay the historical excesses through offsets against their FY2027 fees.

How much does IperionX expect to pay its non-executive directors in FY2027?

Net NED cash fees are currently expected to total US$128,392 after agreed offsets. If shareholders approve the proposed increase to the fee pool, the company expects net FY2027 fees of US$288,392 after deductions.

What fee-pool increase is IperionX asking shareholders to approve?

IperionX is seeking approval to increase the aggregate NED fee pool to US$700,000. If approved, the company proposes to restore historical NED cash fee rates while continuing to deduct the agreed offsets for historical excess payments in FY2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM 6-K


REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of the
Securities Exchange Act of 1934

Date: November 19, 2026.

Commission File Number: 001-41338


IperionX Limited
(Translation of registrant’s name into English)


1092 Confroy Drive
South Boston, Virginia
(Address of principal executive offices)



Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒
 
Form 40-F ☐




EXHIBIT INDEX

The following exhibits are filed as part of this Form 6-K:
 
Exhibit
 
Description
   
99.1
 
Press Release


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 
IPERIONX LIMITED
 
(registrant)
   
Date:
November 19, 2026.
By:
/s/ Marcela Castro
 
Name:
Marcela Castro
 
Title:
Chief Financial Officer



Exhibit 99.1
 
 
PRESS RELEASE | NASDAQ: IPX | ASX: IPX
 
November 19, 2026

NON-EXECUTIVE DIRECTOR FEES
 
IperionX Limited (NASDAQ: IPX; ASX: IPX) (IperionX or the Company) advises that it has identified a breach of ASX Listing Rule 10.17A, which provides that the total amount of directors’ fees paid to directors of an entity or its child entities must not exceed the aggregate amount approved by security holders under Listing Rule 10.17.
 
On 25 November 2021, shareholders approved an aggregate annual cash fee pool of US$300,000 for non-executive directors (NEDs). In July 2026, Michael Loparco joined the Board. In reviewing his proposed cash compensation, the Company identified the existing fee pool limit and determined that excess fees had been paid to NEDs in prior financial years.
 
The Board’s review determined that aggregate NED cash fees exceeded the approved fee pool by US$13,804, US$38,796 and US$119,007 in FY2024, FY2025 and FY2026, respectively. The failure to seek shareholder approval for an increase in the fee pool was an administrative oversight.

The Company promptly took remedial action by reducing aggregate gross NED cash compensation for FY2027 to US$300,000, including superannuation, effective 1 July 2026. The five existing NEDs were each allocated a gross annual fee of US$60,000 before repayment offsets. The newest director, Michael Loparco, will receive no cash compensation for FY2027 unless shareholders approve an increase in the fee pool.

The affected directors have agreed to repay the historical excess fees through offsets against their FY2027 fees. After these offsets, the aggregate net NED cash fees currently expected to be paid for FY2027 total US$128,392, or approximately US$26,000 per paid NED.

As detailed in the Company’s Notice of Annual General Meeting released on 15 October 2026, the Company is seeking shareholder approval to increase the aggregate NED fee pool to US$700,000. If the resolution is passed, the Company proposes to restore NED cash fees to the historical rates paid in prior years, as described in the 2026 Annual Report, while continuing to deduct the agreed offsets for historical excess payments from the amounts otherwise payable in FY2027.

Historically, NED fees were based on an annual director fee of US$50,000, with additional fees for committee service and for the Lead Independent Director role. These arrangements resulted in annual fees ranging from US$65,000 to US$90,000 per director, averaging approximately US$76,666 before repayment offsets. If the aggregate fee pool is increased, the aggregate net NED cash fees expected to be paid for FY2027, after the agreed deductions, would total US$288,392, or approximately US$48,065 for each of the six NEDs.

The Board considers that the historical excess payments are being addressed through the agreed repayment offsets. The Company has also strengthened its procedures to monitor compliance with the approved aggregate NED fee pool. Before each quarterly director fee payment, proposed fee increase or appointment of an additional NED, the Company will review fees paid and forecast for the financial year against the applicable cap. The Board believes these measures provide appropriate safeguards against recurrence.
 
This announcement has been authorized for release by the CEO and Managing Director.
 
For further information or inquiries, please contact:
 
info@iperionx.com 
+1 980 237 8900
 


Virginia
Tennessee
Utah

1092 Confroy Drive
South Boston, VA 24592
279 West Main Street
Camden, TN 38320
1782 W 2300 S
West Valley City, UT 84119
IperionX Limited ABN 84 618 935 372
   

Filing Exhibits & Attachments

1 document

Keep reading